Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Faruqi & Faruqi LLPSPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in ARS Pharmaceuticals between March 9, 2026 and June 24, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]New York, New...
- Phio Pharmaceuticals Corp.Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceKing of Prussia, Pennsylvania--(September 11, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company developing therapeutics based on its proprietary INTASYL® siRNA gene-silencing technology designed to eliminate cancer, today announced that members of its management team will be available for one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York...
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARDWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Aardvark’s February 13, 2025 initial public offering (“IPO”); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the “Class Period”), of the important October 13, 2026 lead plaintiff deadline.
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today provides an update on its development strategy for eftilagimod alfa (“efti”).
- Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical TrialClearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorder (“AUD”) in its ongoing clinical trial evaluating CMND-100, the Company’s proprietary psychedelic-based treatment candidate for AUD.
- Tempest TherapeuticsTempest Therapeutics Announces Up to $7.5 Million Private Placement$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants
- GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time.
- Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration StatementAllarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registrat
- Eloxx Pharmaceuticals, Inc.Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport SyndromeFirst two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected by the end of 2027 — Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a...
- HmediumFrost & Sullivan presents the "GLOBAL GENE THERAPY CRDMO TECHNOLOGY INNOVATION LEADERSHIP AWARD" to PackGene Biotech Inc.On August 4, the 20th Frost & Sullivan Global Growth, Innovation and Leadership (GIL) Summit and the 5th New Investment Event (the "2026 Frost & Sullivan New Investment Event") officially opened at Jing An Shangri-La, Shanghai.In conjunction with the Summit, the Celebratory Banquet for the 65ᵗʰ Anniversary of Frost & Sullivan Global and the 20ᵗʰ Anniversary of the GIL Summit in China was held, where the 2026 Frost & Sullivan Global Awards...
- Nanoscope TherapeuticsNanoscope Therapeutics to Participate in the 28th Annual H.C. Wainwright Global Investment ConferenceSulagna Bhattacharya, Chief Executive Officer, to deliver corporate presentation on Monday, September 14, 2026 — New York, September 11, 2026 — Nanoscope Therapeutics, Inc., a biotechnology company committed to developing and commercializing novel,...
- Pharmaceutical Regulatory Affairs in Asia Online Training Set for March 3–5, 2027 — Registration Now OpenEvolving Asian pharma regulations are driving demand for expertise in market entry, clinical trials, product registration and lifecycle compliance for innovative drugs and generics.